MedTrace Logo

Serum Clozapine and Cognition

NCT00951418 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2013-09-12

No results posted yet for this study

Summary

This study aim to investigate the relationship between serum levels of clozapine and cognitive performance in patients with ICD-10 Schizophrenia and treated with clozapine monotherapy. The hypothesis is that higher serum levels of clozapine are associated with cognitive dysfunctions. Furthermore, ECG changes and the relation to serum level of clozapine are studied. The design is cross-sectional.

Conditions

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Rene Ernst Nielsen, M.D. · Aalborg Psychiatric Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-03-31
Completion
2013-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951418 on ClinicalTrials.gov